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in the individual patients. MetaHeps testing could also rule 
out DILI and help to identify other causes of acute liver in-
jury. Moreover, MetaHeps identified the causative agent in 
polymedicated patients. In conclusion, in vitro  research of 
idiosyncratic DILI requires individual cell models which pro-
duce results comparable to the clinical situation. We suggest 
the MetaHeps technology as a novel tool to cope with these 
challenges of DILI.  © 2015 S. Karger AG, Basel 
 Introduction 
 Drug-induced liver injury (DILI) is the major cause for 
acute liver failure in the industrial world  [1–3] . Addition-
ally, it is a relevant burden for pharmaceutical develop-
ment as one of the major causes for regulatory actions, 
market withdrawals and project terminations  [4] .
 DILI is often classified as either dose dependent, with 
acetaminophen (paracetamol, APAP) as the most impor-
tant example, or idiosyncratic, usually developing after a 
latency of several weeks to months, affecting only a few 
susceptibilities without clear dose dependency (table 1) 
 [5] . Substantial progress has been achieved in developing 
cellular and animal models to better predict and identify 
drugs with the risk for dose-dependent hepatotoxicity. 
Yet the problem of idiosyncratic DILI is still unsolved, 
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 Abstract 
 Drug-induced liver injury (DILI) is the most common cause of 
acute liver failure and accounts for the majority of regula-
tory actions on drugs. Furthermore, DILI is a relevant cause 
for project terminations in pharmaceutical development. 
The idiosyncratic form of DILI is especially a threat in late 
clinical development phases and postmarketing, respective-
ly. Even the occurrence of only a few idiosyncratic DILI cases 
in late clinical development or postmarketing may suffice to 
terminate or withdraw an otherwise promising therapy. De-
spite advances in preclinical assessment of dose-dependent 
toxicity, idiosyncratic DILI is still a big challenge for in vitro 
research: it not only requires individualized models but also 
a huge number of tests. We have developed and investigat-
ed MetaHeps ® , a technology involving hepatocyte-like cells 
generated from peripheral monocytes without genetic 
modifications. These cells exhibit several hepatocyte-like 
characteristics and show donor-specific activities of drug-
metabolizing enzymes. With MetaHeps we have performed 
in vitro investigations in patients with DILI suspicion. By in-
vestigating MetaHeps derived from DILI patients we could 
show increased in vitro  susceptibility to the drugs involved 
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since individual susceptibility of the patient is the major 
determinant for this form of hepatotoxicity. In contrast 
to dose-dependent DILI, which can be discovered in pre-
clinical development, idiosyncratic reactions are often 
only recognized in the late-stage clinical development of 
a drug, when a substantial number of patients are ex-
posed. This review will focus on MetaHeps ® , a novel cell 
model which can reflect idiosyncratic drug toxicity in in-
dividual patients.
 Idiosyncratic DILI and Cell Models 
 Metabolism and detoxification processes in the hepa-
tocyte play an important role in the occurrence of drug 
toxicity  [5] . Since there are substantial metabolism differ-
ences between human and animal livers, primary human 
hepatocytes (PHH) are considered to be the gold standard 
for in vitro hepatotoxicity testing  [6] . Yet the use of PHH 
is limited by their lack of long-term stability in culture and 
the limited availability of cells, as well as a very limited 
number of donors. Progress has been made by improving 
stability through improved culture conditions, taking ad-
vantage of sandwich cultures, cocultures with nonparen-
chymal cells and 3D microtissues. In order to overcome 
the limited availability of cells, tumor cell lines or immor-
talized hepatocytes are an option  [7] . Yet these cell sourc-
es allow no (tumor cells) or limited (immortalized hepa-
tocytes) individualization. Stem cell technologies, espe-
cially induced pluripotent stem cells may be promising 
alternatives (table 2)  [8] . However, to date no data are 
available showing induced pluripotent stem cells reflect-
ing individual susceptibility to drug hepatotoxicity. Fur-
thermore, all these models are applied in the preclinical 
drug development process. Thus, in the view of the rare 
incidence of idiosyncratic DILI, huge numbers of tests 
would be required to exclude the risk of idiosyncratic 
DILI. Therefore, we have developed MetaHeps, a cell 
model that is generated from peripheral monocytes with-
out genetic modifications  [9] . Our data provide evidence 
that MetaHeps show several characteristics of hepatocytes 
necessary for the investigation of drug hepatotoxicity in 
vitro. Moreover, they reflect individual characteristics of 
the donor’s hepatocytes. The cells can be cryoconserved 
and therefore enable the setup of a cellbank and a data-
base. Thus far, MetaHeps have been generated and cryo-
preserved from more than 100 donors, including 30 pa-
tients diagnosed with idiosyncratic DILI. Almost 100 
compounds with different levels of DILI concern have 
been tested, resulting in an extensive database.
 The Need for a Test to Positively Diagnose and 
Exclude Idiosyncratic DILI 
 Idiosyncratic DILI is one of the most challenging diag-
noses in hepatology which relies on accurate history, ex-
aminations and exclusion of other possible etiologies for 
liver injury  [10] . The current gold standard for the diag-
nosis is expert opinion, sometimes accompanied by stan-
dardized causality assessment methods such as the
CIOMS/RUCAM score  [11] . Even if DILI can be estab-
lished as the most likely diagnosis, polypharmacy can 
preclude the identification of the causative drug. On the 
other hand, there is also evidence that liver injuries of 
other etiology are often misdiagnosed as DILI  [12] .
 An important feature in assessing causality of a drug is 
the typical signature, consisting, for example, of a typical 
time to onset or pattern of injury. Such a signature can 
only be described once DILI has happened and, therefore, 
is not available before late-stage development or the mar-
keting of novel drugs. Diagnostic uncertainty, in combi-
nation with the risk of fatal liver injury, requires careful 
evaluation when increased frequencies of liver enzyme 
elevations are observed during clinical trials. Until now, 
no reliable laboratory test to assess causality of the respec-
tive drug is available  [13] . Thus, the actual DILI risk might 
be overestimated and promising drugs are potentially be-
ing discarded due to safety concerns. Currently, there is 
no solution to the challenge that DILI poses on drug de-
velopers and regulators: combining maximum patient 
safety with efficient drug development processes, avoid-
ing unnecessary losses of drugs and investments  [14, 15] .
 Current risk minimization strategies rely on patterns 
and frequencies of liver enzyme elevations. For example, 
the occurrence of only one or two ‘Hy’s law’ cases [alanine 
aminotransferase (ALT) elevation >3ULN and bilirubin 
>2ULN] in combination with a higher incidence of low-
grade elevations in the treatment populations in compar-
ison to a control group might lead to discontinuation of a 
drug  [16] . The great impact of even a single suspected case 
of severe DILI highlights the false importance of false-pos-
itive DILI diagnosis. False-positive results increase the 
risk of innovative drugs to be terminated, depriving pa-
tients of effective new treatments and causing investment 
losses. Thus, a diagnostic test will not only have to provide 
high sensitivity, excellent specificity is even more impor-
tant in cases of rare events such as DILI  [17, 18] . There-
fore, there is urgent need for technologies which provide 
objective data to diagnose or exclude DILI in individual 
patients and also allow the assessment of causality of a 
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 MetaHeps as a Tool in the Diagnosis of Idiosyncratic 
DILI 
 Since MetaHeps reflect individual hepatocyte charac-
teristics of the donor, their performance as a test for idio-
syncratic DILI is being investigated in our ongoing study 
in idiosyncratic DILI patients. The control group is repre-
sented by patients with acute liver injury and the intake of 
at least one drug. Additional inclusion criteria are defined 
according to Aithal et al.  [12] as: ALT  ≥ 5ULN, alkaline 
phosphatase (AP)  ≥ 2ULN or ALT  ≥ 3ULN accompanied 
by a bilirubin elevation  ≥ 2ULN. For the diagnosis or ex-
clusion of DILI, the patient’s history is obtained as well as 
clinical information, as proposed by Agarwal et al.  [19] . 
Routine laboratory investigations include ALT, aspar-
tate aminotransferase (AST), AP, γ-glutamyltransferase 
(GGT), bilirubin, international normalized ratio and 
blood cell counts. Virological testing for hepatitis A, B, C 
and E, as well as for HIV, cytomegalovirus and Epstein-
Barr virus is performed and extended when the history 
provided evidence. Autoimmune hepatitis is diagnosed or 
excluded using ANA, IgG and, where indicated, liver bi-
opsy. Each patient is examined by ultrasonography to ex-
clude cholestasis; CT scan and IMR (liver MR and MRCP) 
are performed when additional imaging is deemed neces-
sary. The RUCAM score is calculated for each patient and 
information on drug hepatotoxicity signatures is obtained 
using the LiverTox website  [20] .
 After informed consent is obtained, MetaHeps are 
generated and tested with the drugs that are implicated in 
the respective case. Toxicity is determined by the mea-
surement of lactate dehydrogenase in supernatant and 
cell lysate. Since the method allows the testing of several 
drugs using cells of the same donor, in vitro testing also 
includes drugs that were known to be tolerated by the pa-
tient. A typical result obtained with MetaHeps from a 





















 Fig. 1. Spiderweb graph of the results ob-
tained by testing drug toxicity in MetaHeps 
of a DILI patient. A toxicity of >90% was 
observed by incubation with the drug O 
that was clinically suspected to have caused 
DILI in this patient. When tested in Meta-
Heps of healthy donors, O (10 μ M ) did not 



















Affects all individuals with 
exposure exceeding critical 
dose
Affects only susceptible individu-
als at low frequency (e.g. 1 in 
10,000)
Clearly dose-related No obvious dose dependency 
Short latency (days) Variable, but usually long latency: 
weeks, months or even years
Distinctive liver lesion Can mimic nearly every known 
liver disease 
Predictable in vitro and in 
animals
Usually not predicted by routine 
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 So far, in our 50 patients there has been no false-pos-
itive result and only 2 DILI patients were missed by Me-
taHeps. In the case of patients with polymedication, 
MetaHeps could help to identify the causative agent (an 
example is shown in  fig. 2 )  [29] . These promising results 
warrant further validation in a larger patient sample. 
MetaHeps were also able to reproducibly reflect indi-
vidual drug sensitivity even months after the DILI 
event.
 Impact of Positive Identification of DILI Patients and 
the Causative Drug on Biomarker Development 
 Due to the low frequency of hepatotoxicity observed 
even with withdrawn drugs (e.g. with troglitazone only 
1.9% of patients developed liver enzyme elevations  [17, 
21] ), identification of susceptibility factors has been pro-
posed. Such predictive factors should solve the dilemma 
of drug developers and regulators achieving both patient 















X 100 MY 10 M
Y 100 M
Y 100 M M
Y 100 M M
Y 100 M + X 50 M
Y 100 M M
 Fig. 2. Spiderweb graph of the results ob-
tained by testing drug toxicity in Meta-
Heps. This patient experienced DILI dur-
ing treatment with drugs X and Y. RUCAM 
and available data on drug signatures could 
not help to identify the causative drug. In 
MetaHeps of this patient, drug X caused 
toxicity in clinically relevant concentra-
tions, whereas drug Y showed no effect 
(both drugs showed no toxicity in the used 
concentrations in MetaHeps from healthy 
donors; data not shown). The combination 
of X and Y yielded the same results as drug 
X alone. Therefore, X seems to be respon-
sible for DILI in this patient, whereas Y is 
cleared and there is no evidence for a rele-
























Reflection of individual 
hepatotoxicity
PHH
Conventional ++ – – + no data
3D ++ ++ – + no data
Immortalized + – + + no data
Tumor cell lines (examples)
HepG2 + – ++ – –
Huh-7 + – ++ – –
HepaRG + ++ ++ – –
Stem cells
Embryonic + + + – –
Induced pluripotent + + + + no data
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safety and successful marketing of novel and innovative 
drugs. Among individual factors such as age, gender, al-
cohol consumption and comedication, etc., genetic risk 
factors have also been identified  [22] . Most interestingly, 
genetic polymorphisms in hepatic metabolism and trans-
port are very variably linked to the DILI risk, whereas the 
closest association was shown for flucloxacillin and the 
human leukocyte antigen HLA-B * 5701 with an OR of 80.6 
 [23] . These findings suggest an important role for immu-
nological mechanisms. In order to identify a safety bio-
marker a similar approach was used to rescue lumiracox-
ib, a COX-2 inhibitor, that caused liver enzyme elevations 
in only 3% of treated patients  [24] and was implicated in 
several cases of severe liver injury. HLA (human leukocyte 
antigen) polymorphisms (the strongest association was 
with HLA-DRB1 * 1501) could be identified by a genome-
wide association study, yielding a positive predictive value 
of only 0.08  [25] . For this study, patients were selected by 
ALT and/or AST  ≥ 3ULN under lumiracoxib and com-
pared to a lumiracoxib-treated control group without liv-
er enzyme elevations. The clinical relevance of such find-
ings may be limited since, in contrast to the flucloxacillin 
study, most patients exhibiting this polymorphism were 
asymptomatic  [26] . Thus, differentiation may be difficult 
between frequent asymptomatic elevations of liver en-
zymes and rare but severe DILI. In order to develop more 
effective biomarkers, unequivocal diagnosis of DILI and 
precise identification of the DILI-causing agent are piv-
otal, yet even in thoroughly performed studies it may not 
be possible to verify the diagnosis in up to 25% of cases 
 [27] . Therefore, a test that allows the diagnosis or exclu-
sion of DILI and identification of the causative agent may 
prove very valuable for the development of efficient bio-
markers, especially for novel drugs where causality assess-
ment is limited by lack of a known drug ‘signature’ [28].
 Conclusion and Perspectives 
 Idiosyncratic DILI is still a diagnosis of exclusion and 
consensus expert opinion following a thorough evalua-
tion is the current gold standard for establishing causality 
in patients with suspected DILI. In combination with 
causality assessment scores such as RUCAM the diagno-
sis can be ascertained in many cases, yet polymedication 
may make it impossible to identify a single causative 
agent or to clear a drug from the DILI suspicion. These 
remaining uncertainties require novel methods that en-
able the positive diagnosis of DILI and, moreover, iden-
tify the drug causing DILI in the individual patient. Our 
investigations with MetaHeps have shown that hepato-
cyte-like cells derived from peripheral monocytes pro-
vide promising data. We suggest that this approach 
should be further evaluated. 
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